Overcoming Barriers to Treatment in AD
An expert discusses the most common barriers clinicians face when prescribing topical therapies for atopic dermatitis (AD) and their impact on patient adherence as well as strategies dermatologists can employ to navigate insurance coverage, prior authorization and step therapy to ensure patients receive appropriate care.
Video content above is prompted by the following:
- What are the most common barriers clinicians face when prescribing topical therapies for AD, and how do they impact patient adherence?
- What strategies can dermatologists employ to navigate insurance coverage, prior authorization and step therapy, and ensure patients receive appropriate care?
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
